Ivzumab 100mg Injection

Ivzumab 100mg injection is an anticancer medicine containing the active ingredient Bevacizumab. This medicine is formulated to inhibit tumour growth. It is indicated in combination with other chemotherapy drugs for the treatment of metastatic breast cancer, brain cancer, cervical cancer, kidney cancer, lung cancer, and colorectal cancer. It is also used in cancers of the ovary, fallopian tube, and primary peritoneal cancer. Effective contraception should be used during treatment and for at least six months following the final dose. Ivzumab 100mg injection is not recommended for adolescents and children below 18 years of age. Discuss with your doctor the preservation of ovarian tissue if pregnancy is planned in the near future, as this medicine may cause fertility issues in women. Breastfeeding should be avoided as this medicine may interfere with infant growth and development. Ivzumab 100mg injection is typically administered in combination with other chemotherapy agents. Constipation, decreased appetite, rhinorrhoea, fever, skin reactions, and weight loss are common side effects of Ivzumab 100mg injection. Before initiating treatment with this medicine, inform your doctor if you have hypertension, hyperglycaemia, gastrointestinal disorders, or cardiac problems. This medicine should not be administered for 28 days before and after surgery due to the risk of impaired wound healing and increased bleeding complications. It is advisable to report any dental issues requiring surgical intervention to your doctor prior to commencing this medicine. Should visual disturbances or confusion develop, report to your doctor to prevent complications.

Glioblastoma multiforme (brain cancer) Persistent, recurrent, or metastatic breast cancer Metastatic cervical cancer Advanced kidney cancer Metastatic colorectal cancer Advanced non-small-cell lung cancer Liver Cancer- Hepatocellular carcinoma Cancers of the ovary, cervical, fallopian tube, or primary peritoneal cancer

Ivzumab 100mg injection is a recombinant humanized monoclonal antibody that works as a targeted therapy in the treatment of various advanced cancers. It produces its action by selectively binding to the protein called vascular endothelial growth factor A (VEGF-A), present in the lining of blood and lymph vessels in the body. It interrupts the interaction of VEGF-A with its receptors. This further inhibits the formation of blood vessels that supply oxygen and nutrients to the tumor. As a result, it slows down the rate of progression of cancer.

Your physician or nurse will administer Ivzumab 100mg injection as an intravenous infusion. The infusion should be given immediately after the dilution.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Severe allergic reactions High Blood pressure Delayed wound healing following surgery Severe infections Blood clots in arteries and blood vessels of lungs Gut perforation Nosebleeds and bleeding risk Heart problems with an increase in heart rate Shortness of breath Common Numbness in hands or feet Weakness and lack of energy Diarrhoea, nausea, vomiting, abdominal pain Constipation Loss of appetite Weight loss Changes in taste and speech Decrease in counts of white blood cells Fever Dry skin Back pain

It is vital to inform your physician before taking Ivzumab 100mg injection if you have the following conditions: Have conditions involving inflammation in the stomach (ulcer, colitis). Experience allergic reactions to Bevacizumab or its ingredients. Have recently undergone surgery as it is associated with the risk of bleeding. Have diabetes, hypertension, or heart problems.